Johnson & Johnson (NYSE:JNJ) announced on Wednesday that the European Commission approved an injectable version of its blood cancer therapy Darzalex, developed with Halozyme Therapeutics (NASDAQ:HALO) ...
Johnson & Johnson’s (J&J) blockbuster oncology asset, Darzalex Faspro (daratumumab and hyaluronidase-fihj) has gained US approval in smouldering multiple myeloma (sMM). J&J’s CD38-targeting monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results